Creative Biolabs is a specialized microbiome CRO serving biotech, food, and pharma R&D teams. We deliver end-to-end solutions for strict anaerobes like Blautia producta—from isolation and strain analytics to mechanism-rich models and scalable bioprocess packages—so you can move faster with transparent, decision-grade data.
Chosen by organizations that demand rigorous anaerobic workflows, transparent data packages, and scientifically validated results.
B. producta sits at the intersection of carbohydrate fermentation, short-chain fatty acid (SCFA) biogenesis, and immune-metabolic signaling, making it attractive for preclinical microbiome research. Yet its oxygen sensitivity and strain-specific phenotypes demand purpose-built methods, sealed logistics, and quantitative endpoints that go far beyond routine culture.
Creative Biolabs brings a tightly controlled <0.1% O2 platform, integrated -omics, and mechanism-to-model workflows tailored to B. producta. You receive curated strain banks, MoA-linked assay panels, and scale-up parameters aligned to formulation needs—each step documented to accelerate internal decision making.
Fig.1 Morphology of B. producta. 1
Under <0.1% O2, we isolate/purify B. producta from human or animal samples, then rapidly screen growth curves, SCFA productivity, substrate use, and initial oxygen/bile tolerance phenotypes. We rank candidates for development potential, retaining full chain-of-custody and establishing seed stocks for repeatable downstream experiments.
We pinpoint B. producta to the strain level via full-length 16S and/or whole-genome sequencing (ANI/MLST), supported by MALDI-TOF and biochemical profiles. This resolves confusion with closely related Blautia species and issues an audit-ready “strain passport” for traceability across studies and sites.
We quantify endpoints around SCFA output, carbon flux, microbe–microbe interactions, and bile acid remodeling. Readouts include barrier integrity (TEER), tight-junction protein status, and GPCR/HDAC-linked signaling. Your result is a coherent, transparent evidence package that links B. producta activity to interpretable mechanism claims.
Using Caco-2/HT29-MTX/intestinal organoids co-cultured with immune cells (macrophage/dendritic), we assess barrier integrity, adhesion/colonization potential, and cytokine landscapes (IL-8/IL-10/TNF-α). These assays situate B. producta within gut-relevant ecology and help position strain functions against epithelial and innate immune endpoints.
We construct fermentation fingerprints for inulin, FOS, resistant starch, and mixed-linkage β-glucans. Using GC-FID/GC-MS, we quantify acetate/propionate/butyrate and lactate, illuminating B. producta substrate preferences and product flux to guide formulation and expected in vivo functionality. Gene-locus insights for β-glucan use are available.
We scale B. producta from shake flasks to 10–50 L with strict ORP/pH/feed control to maximize CFU and metabolic consistency. You receive a process parameter dossier (acidogenesis kinetics, volatile profile, impurity spectrum) plus hold-time guidance—foundations for subsequent formulation and stability engineering.
For oxygen-sensitive strains, we develop delivery prototypes: freeze-drying or spray-drying with protectants (e.g., alginate, trehalose, skim milk) and low-oxygen packaging. Options include enteric, microencapsulated, or lyophilized formats. We test rehydration recovery, simulated GI survival, and shelf-life to align B. producta with realistic logistics.
RUO safety analytics include genome risk locus/virulence factor scans, mobile/transferable AMR genes and MIC panels, endotoxin/phage/exogenous contamination monitoring. These outputs map to common pre-clinical expectations for live biotherapeutic research and help prepare dossiers for internal governance and partner reviews.
Align hypotheses, matrices, and endpoints; finalize isolation sources, substrates, and MoA readouts in a signed work plan.
Enrich, isolate, and purify B. producta under <0.1% O₂ with chain-of-custody and contamination gates.
Apply WGS/ANI/MLST and MALDI-TOF; issue a traceable strain passport with QC thresholds.
Run SCFA flux, epithelial barrier/immune crosstalk, and bile acid remodeling assays with appropriate controls.
Transfer best strains to controlled bioprocess and prototype formulations; quantify stability and function.
Provide raw/processed data, SOPs, and tech transfer support; iterate or expand into new models as needed.
End-to-end, low-oxygen handling, sealed logistics, and validated recovery checkpoints.
Barrier, immune, and receptor-linked endpoints translate microbial outputs into actionable biology.
WGS/ANI/MLST differentiates B. producta from close neighbors; everything is traceable.
ORP/pH-controlled runs provide CFU consistency and impurity awareness for development decisions.
Clean raw files, analysis scripts on request, and SOPs to satisfy internal review boards.
Creative Biolabs scientists integrate your constraints, timelines, and go/no-go criteria from day one.
Using B. producta, researchers probe lipid and glucose regulation in diet-induced models. Platforms quantify 12-methylmyristic acid, SCFA profiles, and host markers, prioritizing strains that shift adipocyte accumulation, hepatocyte readouts, and metabolic signaling.
With B. producta, colitis models measure barrier integrity, cytokines, and histology across fiber or bile-acid contexts. TEER, tight-junction proteins, and SCFAs quantify anti-inflammatory potential and situate strains within gut ecology and epithelial outcomes.
Consortia studies with B. producta examine colonization resistance. Lantibiotic activity, niche occupancy, and metabolite competition are measured with Enterococcus challenge readouts, clarifying community roles and informing combination designs for microbiome-based pathogen exclusion research.
B. producta platforms quantify immune pathway modulation with macrophage or dendritic co-cultures. Cytokines, TLR4/NF-κB reporters, and GPCR/HDAC assays connect microbial outputs to host signaling; epithelial readouts track adhesion, colonization potential, and barrier support.
B. producta enables targeted nutrition research on inulin, FOS, resistant starch, and mixed-linkage β-glucans. Fermentation fingerprints, SCFA yields, and cross-feeding effects inform fiber selection, dose, and formulation for desired gut-metabolite and community outcomes.
Prebiotic screens with B. producta assess growth and function on oligosaccharides, including HMOs and tailored FOS. Outputs direct selective promotion strategies that increase Blautia abundance while maintaining favorable metabolites and stable community structure.
Below are several B. producta strains and genomic materials available from Creative Biolabs to support diverse microbiome and molecular research needs.
| Product Name | Catalog No. | Target | Product Overview | Size | Price |
|---|---|---|---|---|---|
| Blautia producta;sludge | LBSX-0522-GF88 | Blautia | Blautia producta (Prevot) Liu et al. was isolated from anaerobic digester sludge. | — | — |
| Blautia producta (Prevot) Liu et al. | LBSX-0522-GF89 | Blautia | Blautia producta (Prevot) Liu et al. was isolated from human septicemia. | — | — |
| Blautia producta;2950 | LBSX-0522-GF90 | Blautia | Blautia producta was isolated from human septicemia. | — | — |
| Blautia producta;14466 | LBSX-0522-GF91 | Blautia | Blautia producta was isolated from human faeces. | — | — |
| Blautia producta Genomic DNA | LBGF-0925-GF1176 | Blautia DNA | Contains high-quality, intact genomic DNA isolated from Blautia producta. Ready-to-use DNA for PCR, qPCR, and Next-Generation Sequencing. | 5 µg | $1,180.00 |
Human stool, animal cecal/colonic contents, and anaerobically preserved biobank material. We recommend rapid, cold, oxygen-minimized transport with reducing agents and immediate processing in <0.1% O₂ chambers to protect viability and maintain native phenotypes.
We combine pre-reduced media, anaerobic chambers with continuous gas monitoring, low-permeability plastics, oxygen-scavenging packaging, and dissolved-oxygen/ORP logging. Each transfer step is validated for recovery rates and recorded in batch documentation and QC reports.
Core panels include SCFA profiles by GC-FID/GC-MS, TEER and tight-junction proteins for barrier integrity, cytokine maps, GPCR/HDAC reporter outputs, and bile acid remodeling by LC-MS. Negative/positive controls and blanks ensure interpretability.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
Copyright © 2025 Creative Biolabs. All Rights Reserved.